EBITDA Margin % is calculated as EBITDA divided by its Revenue. Unipharma Co's EBITDA for the
six
months ended in Dec. 2025 was NT$-13.15 Mil. Unipharma Co's Revenue for the
six
months ended in Dec. 2025 was NT$44.13 Mil. Therefore, Unipharma Co's EBITDA margin for the quarter that ended in Dec. 2025 was -29.80%.
Unipharma Co (ROCO:6621) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Unipharma Co EBITDA Margin % Related Terms
Unipharma Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Unipharma Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6621 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Unipharma Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unipharma Co (ROCO:6621) has a EBITDA Margin % of -29.80% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unipharma Co and its competitors. According to the industry distribution chart, Unipharma Co ranks #834 out of 952 companies in the Drug Manufacturers industry, placing it in the top 87.6%.
Is Unipharma Co's EBITDA Margin % too high?
Unipharma Co's current EBITDA Margin % is -29.80%. Based on the distribution chart, Unipharma Co ranks #834 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unipharma Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #834 out of 952 companies for EBITDA Margin %. This places Unipharma Co in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current EBITDA Margin % is -29.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.67, compared to a current price of NT$11.30 — trading 3.2% below its estimated fair value. The current EBITDA Margin % is -29.80%. Unipharma Co's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current EBITDA Margin % is -29.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.30 is trading 3.2% below its estimated GF Value™ of NT$11.67.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
EBITDA Margin %: -29.80%
GF Value™: NT$11.67 vs. price of NT$11.30 (3.2% below fair value)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
75GF Score
Get the complete analysis for ROCO:6621
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
